Hims, the telehealth startup known for treatments like erectile dysfunction and hair loss, is focusing on maintaining access to GLP-1 medications amidst regulatory pressures. Following a significant supply shortage in 2024, Hims saw substantial revenue growth from its weight loss product, Faux-zempic. However, renewed FDA regulations threaten its market position, leading the company to initiate a campaign encouraging users to advocate for their access to these vital treatments. This movement sees consumers submitting letters to the FDA as a measure of support to counteract regulatory challenges.
I ask you to consider the real, life-changing impact of these treatments. Please ensure that patients continue to have access to compounded GLP-1s as a critical part of health management.
Hims decided to roll out a brave new strategy to combat federal regulations: e-begging.
With all that money on the line, Hims has decided to roll out a brave new strategy to combat federal regulations: e-begging.
Hims bragged that its Faux-zempic brought in a cool $225 million in revenue in 2024, with an estimated $725 million in weight-reduction revenue on the way in 2025.
Collection
[
|
...
]